Here we go again. Cash is dropping. Stock issuance likely. Dilution ahead. Quarterly earnings highlights (BAD): cash and cash equivalents of approximately $13.8 million as of December 31, 2015, compared to approximately $15.3 million as at September 30, 2015.Expenses were approximately $4.5 million, compared to approximately $0.8 millionNet loss was $4.0 million or $0.12 per share, compared to a net loss of approximately $0.8 million or $0.06YoY Expect at least 100 million shares outstanding by next year. O/S shares TRIPLED from 12M to 36M last quarter. Partnership required, or more losses and bleeding for shareholders. ANAVEX 2-73 is still mid-phase and will require more funding to reach completion. The Biotech index (IBB) provides more variety than AVXL.